posted
Aethlon Medical Files Cancer Treatment Patent Aethlon Medical, Inc. (OTCBB:AEMD) disclosed today that it has filed a international patent application under the Patent Cooperation Treaty (PCT) entitled, Extracorporeal Removal of Microvesicular Particles. Microvesicular particles are secreted by tumor cells and are known to depress the immune response in cancer patients. They shield tumor cells from the immune response by inducing T-cell apoptosis and blocking T-cell signaling, proliferation, cytokine production, and cytotoxicity. The patent application augments Aethlon’s intellectual property portfolio, and is associated with early stage research initiatives to evolve the mechanisms of the Aethlon Hemopurifier® to be a potential method to assist in the treatment of cancer. Aethlon’s primary focus is to commercialize the Hemopurifier as the first-in-class device to treat a broad-spectrum of infectious disease conditions. The Patent Cooperation Treaty (PCT) is an international patent law treaty, which provides a unified procedure for filing patent applications to protect inventions in 137 member nations. A patent application filed under the PCT is called an international application or PCT application.
About Aethlon Medical
Aethlon Medical has developed a first-in-class medical device to assist in the treatment of infectious disease. The device, known as the Hemopurifier®, is positioned to be a broad-spectrum treatment for drug and vaccine resistant bioweapons, naturally evolving pandemic threats, and chronic infectious disease targets including Hepatitis-C (HCV) and the Human Immunodeficiency Virus (HIV). On March 6, 2007, Aethlon submitted an Investigational Device Exemption (IDE) to the U.S. Food and Drug Administration (FDA) requesting permission to initiate human safety studies of the Aethlon Hemopurifier® as a treatment countermeasure against select category "A" bioterror threats. Additional studies to demonstrate utility of the Hemopurifier® as a countermeasure against bioterror threats are being conducted with researchers at The Centers for Disease Control and Prevention (CDC), The United States Army Medical Research Institute of Infectious Diseases (USAMRIID), and The Southwest Foundation for Biomedical Research (SFBR). Category "A" bioterror threats are defined by the CDC as agents that pose a risk to national security; are easily disseminated or transmitted from person to person; result in high mortality rates; may cause public panic and social disruption, and require special action for public health preparedness. Global researcher, Frost & Sullivan awarded the Hemopurifier® the 2006 Technology Innovation Award, and The AIDS Institute presented Aethlon with the 2007 Innovative HIV Life Sciences Leadership Award. The Company has also initiated research on a second generation Hemopurifier® that targets the capture of growth factors inherent in the spread of Cancer. More information on Aethlon Medical and the HemopurifierTM technology can be found at www.aethlonmedical.com.
Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the Company’s ability to raise capital when needed, the Company’s ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its products, the Company’s ability to manufacture its products and provide its services, the impact of government regulations, patent protection on the Company’s proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company’s Securities and Exchange Commission filings.
Aethlon Medical, Inc. Jeff Richardson, 858-459-7800 ext. 302 Senior Director, Communications jrichardson*aethlonmedical.com or Dylan Hundley, 646-435-4069 Senior Director, Investor Relations dhundley*aethlonmedical.com
Source: Business Wire (March 20, 2007 - 10:11 AM EDT)
Posts: 443 | From: st.louis | Registered: Dec 2003
| IP: Logged |
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
